{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=100+mg+enteric-coated+aspirin", "query": { "intervention": "100 mg enteric-coated aspirin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=100+mg+enteric-coated+aspirin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T17:45:04.359Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04328883", "title": "Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Platelet Aggregation Inhibitors" ], "interventions": [ { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inova Health Care Services", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 19, "start_date": "2019-07-16", "completion_date": "2019-10-10", "has_results": false, "last_update_posted_date": "2020-04-01", "last_synced_at": "2026-10-01T17:45:04.359Z", "location_count": 1, "location_summary": "Falls Church, Virginia", "locations": [ { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04328883" }, { "nct_id": "NCT01038583", "title": "Aspirin in Reducing Events in the Elderly", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Functional Disability", "Dementia", "Heart Disease", "Stroke", "Cancer", "Bleeding", "Depression" ], "interventions": [ { "name": "100 mg enteric-coated aspirin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hennepin Healthcare Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 19114, "start_date": "2010-01", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2021-04-05", "last_synced_at": "2026-10-01T17:45:04.359Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01038583" }, { "nct_id": "NCT05625334", "title": "Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "ASA", "type": "DRUG" }, { "name": "non-enteric-coated chewable aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vectura, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 86, "start_date": "2022-10-14", "completion_date": "2023-03-09", "has_results": false, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-10-01T17:45:04.359Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Springfield, Missouri", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05625334" }, { "nct_id": "NCT07224347", "title": "Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Functional Disability", "Dementia", "Heart Disease", "Stroke", "Cancer", "Bleeding", "Depression", "Frailty" ], "interventions": [], "intervention_types": [], "sponsor": "Anne Murray", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 19114, "start_date": "2019-07-15", "completion_date": "2026-04-30", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-10-01T17:45:04.359Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224347" }, { "nct_id": "NCT02293395", "title": "A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Coronary Syndrome" ], "interventions": [ { "name": "Acetylsalicylic acid", "type": "DRUG" }, { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Clopidogrel", "type": "DRUG" }, { "name": "Ticagrelor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3037, "start_date": "2015-04-20", "completion_date": "2016-10-14", "has_results": true, "last_update_posted_date": "2017-12-26", "last_synced_at": "2026-10-01T17:45:04.359Z", "location_count": 49, "location_summary": "Alexander City, Alabama • Banning, California • Sylmar, California + 46 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Banning", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02293395" }, { "nct_id": "NCT03805932", "title": "Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hairy Cell Leukemia" ], "interventions": [ { "name": "Moxetumomab Pasudotox-tdfk", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Ruxience", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-10-03", "completion_date": "2029-06-30", "has_results": true, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-01T17:45:04.359Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03805932" }, { "nct_id": "NCT02834403", "title": "L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Triple Negative Breast Cancer" ], "interventions": [ { "name": "L-NMMA", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Amlodipine", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Enteric-coated aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 37, "start_date": "2016-11", "completion_date": "2021-01", "has_results": true, "last_update_posted_date": "2023-12-15", "last_synced_at": "2026-10-01T17:45:04.359Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02834403" }, { "nct_id": "NCT05625347", "title": "Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obstructive Pulmonary Function", "Restrictive Pulmonary Function" ], "interventions": [ { "name": "single dose (100 mg) of ASA", "type": "DRUG" }, { "name": "single dose (162 mg) of non-enteric-coated chewable aspirin tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vectura, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 4, "start_date": "2023-03-11", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-10-01T17:45:04.359Z", "location_count": 4, "location_summary": "Orlando, Florida • Winter Park, Florida • Baltimore, Maryland + 1 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Winter Park", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Berlin", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05625347" }, { "nct_id": "NCT00501059", "title": "A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate Risk of CVD" ], "interventions": [ { "name": "Aspirin (Acetylsalicylic acid, BAYE4465)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 12546, "start_date": "2007-07-05", "completion_date": "2016-11-15", "has_results": true, "last_update_posted_date": "2018-10-26", "last_synced_at": "2026-10-01T17:45:04.359Z", "location_count": 73, "location_summary": "Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Graysville", "state": "Alabama" }, { "city": "Pell City", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00501059" }, { "nct_id": "NCT01968798", "title": "ASPREE Cancer Endpoints Study", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Aspirin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hennepin Healthcare Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 14500, "start_date": "2013-09", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2021-04-05", "last_synced_at": "2026-10-01T17:45:04.359Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01968798" } ] }